Although the MEK Inhibitor in Low-Grade Serous Ovarian Cancer Study did not meet its primary end point, binimetinib showed activity in LGSOC across the efficacy end points evaluated. A higher response to chemotherapy than expected was observed and KRAS mutation might predict response to binimetinib.
No takes yet. Share an insight, caveat, or question.
Monk et al. (2020) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: